Hazard ratio and relapse incidence at 3 PML-RARα NQ levels in follow-up period (FUP) samples from 70 INT0129 cases after completion of consolidation chemotherapy
| NQ cutoff . | Relapses/patients . | HR5-150,5-151 . | P5-151 . |
|---|---|---|---|
| Greater than 10−5 | 10/13 | 17.5 | < .001 |
| Less than 10−5 | 13/57 | ||
| Greater than 10−6 | 15/25 | 7.6 | < .001 |
| Less than 10−6 | 8/45 | ||
| Greater than 10−11 | 19/46 | 5.8 | .002 |
| Negative | 4/24 |
| NQ cutoff . | Relapses/patients . | HR5-150,5-151 . | P5-151 . |
|---|---|---|---|
| Greater than 10−5 | 10/13 | 17.5 | < .001 |
| Less than 10−5 | 13/57 | ||
| Greater than 10−6 | 15/25 | 7.6 | < .001 |
| Less than 10−6 | 8/45 | ||
| Greater than 10−11 | 19/46 | 5.8 | .002 |
| Negative | 4/24 |
Data are based on the analysis of at least one evaluable FUP sample with the patient entering the poor-risk category, as defined in Table 4, at the time point that the NQ rises above the indicated cutoff level. Abbreviations are explained in Table 4.
The hazard ratio indicates the relative risk of relapse in poor-risk versus good-risk cases calculated at 3 selected cutoff levels.
Adjusted for the maintenance treatment, PML-RARα type, and pretreatment WBC count.